BioCardia Inc logo

BCDA - BioCardia Inc News Story

$4.2 0.2  4.7%

Last Trade - 13/04/21

Micro Cap
Market Cap £47.7m
Enterprise Value £32.1m
Revenue £106k
Position in Universe 5462nd / 6841

BioCardia, Inc. Announces $10.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Wed 16th December, 2020 1:30pm
For best results when printing this announcement, please click on link below:

SAN CARLOS, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc.
(Nasdaq: BCDA) (BioCardia or the “Company”) today announced it has
entered into definitive agreements with investors for the purchase and sale of
2,038,836 shares of its common stock at a purchase price of $5.15 per share in
a registered direct offering priced at-the-market under Nasdaq rules. The
closing of the offering is expected to occur on or about December 18, 2020,
subject to the satisfaction of customary closing conditions.

A.G.P./Alliance Global Partners is acting as sole placement agent for the

This offering is being made pursuant to an effective shelf registration
statement on Form S-3 (File No. 333- 249426) previously filed with the U.S.
Securities and Exchange Commission (the “SEC”). A prospectus supplement
describing the terms of the proposed offering will be filed with the SEC and
will be available on the SEC’s website located at
Electronic copies of the prospectus supplement may be obtained, when
available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th
Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at Before investing in this offering, interested
parties should read in their entirety the prospectus supplement and the
accompanying prospectus and the other documents that the Company has filed
with the SEC that are incorporated by reference in such prospectus supplement
and the accompanying prospectus, which provide more information about the
Company and such offering.

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of
any such state or jurisdiction.

About BioCardia®
BioCardia, Inc., headquartered in San Carlos, California, is developing
regenerative biologic therapies to treat cardiovascular and respiratory
disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell
therapies are the Company’s biotherapeutic platforms in clinical
development. The Company's products include the Helix Biotherapeutic Delivery
System and its steerable guide and sheath catheter portfolio. BioCardia also
partners with other biotherapeutic companies to provide its Helix system and
clinical support for their programs studying therapies for the treatment of
heart failure, chronic myocardial ischemia and acute myocardial infarction.
For more information, visit

Forward Looking Statements
This press release contains certain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934 and Private Securities Litigation Reform Act,
as amended, including those relating to the timing and completion of the
proposed offering and other statement that are predictive in nature.  These
statements may be identified by the use of forward-looking expressions,
including, but not limited to, “expect,” “anticipate,” “intend,”
“plan,” “believe,” “estimate,” “potential,” “predict,”
“project,” “should,” “would” and similar expressions and the
negatives of those terms.  These statements relate to future events and
involve known and unknown risks, uncertainties and other factors which may
cause actual results, performance or achievements to be materially different
from any results, performance or achievements expressed or implied by the
forward-looking statements. Such factors include the risk factors set forth
in the Company’s filings with the SEC, including, without limitation, its
Annual Report on Form 10-K for the year ended December 31, 2019, its periodic
reports on Form 10-Q, and its Current Reports on Form 8-K filed in 2020, as
well as the risks identified in the shelf registration statement and the
prospectus supplement relating to the offering. Prospective investors are
cautioned not to place undue reliance on such forward-looking statements,
which speak only as of the date of this press release. BioCardia undertakes no
obligation to publicly update any forward-looking statement, whether as a
result of new information, future events or otherwise.

Media Contact:
Michelle McAdam, Chronic Communications, Inc.
Phone: 310-902-1274

Investor Contact:
David McClung, Chief Financial Officer
Phone: 650-226-0120 


GlobeNewswire, Inc. 2020
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.